-
Test-and-treat and high viral suppression do not necessarily translate into reduction of HIV incidence An editorial about three new studies highlights the existence of various effects of universal test-and-treat strategies in high-burden settings, which result in modest to no reductions in HIV incidence
-
Dysregulation of kynurenine metabolism and abdominal fat: a source of inflammation in HIV In well, treated people with HIV, abdominal fat accumulation is associated with activation of pro-inflammatory pathway of kynurenine metabolism, reduction of anti-inflammatory molecules and an increase in systemic inflammation
-
Tattooing: refusing to tattoo people living with HIV is illegal discrimination, new statement confirms. Collecting information on HIV status before tattooing or cosmetic procedures is not justifiable, but cosmetic surgery requires full medical history.
-
Safety and efficacy data are lacking regarding isoniazid preventive therapy in pregnant women who are receiving antiretroviral therapy.
-
Rehospitalisation after heart failure is higher in people with HIV US study shows that risk for heart failure and all-cause rehospitalisation is higher in people living with HIV compared with uninfected controls
-
SMC gives positive decision on Dovato (dolutegravir/lamivudine). Scottish patients first in the UK to access single tablet regimen that combines dolutegravir and lamivudine.
-
We report a successful allogeneic transplantation and long-term engraftment of CRISPR–Cas9–edited stem cells in a patient with HIV and acute lymphoblastic leukemia.
-
Children living with HIV need for optimal antiretroviral formulations During its last meeting, the Paediatric Antiretroviral Drug Optimization group updated the list of priority antiretroviral formulations in children, highlighted advantages of long-acting or extended-release products in the paediatric care and focused on the importance of optimal treatment of pregnant and lactating women
-
London becomes a Fast-Track City in the fight against HIV Ending stigma is key to achieving target of ‘zero HIV’ by 2030
-
New HIV diagnoses in the UK down 28% since 2015 New UK diagnoses of HIV are now at their lowest level since 2000.
-
Test-and-treat antiretroviral therapy can reduce HIV impact at population-level Adoption of test-and-treat programmes improves therapy access and viral suppression compared with most restrictive treatment initiation policy
-
Barriers to care and poor mental health increase mortality after HIV testing People who undergo HIV testing should be screened for barriers to care and poor mental health, both factors associated with an increase in 5-years mortality risk, regardless of HIV status
-
New guideline on the management of candidiasis in people with HIV. Frequency of oropharyngeal candidiasis has fallen but remains high compared with other opportunistic infections.
-
WHO revised the guidelines on hormonal contraceptive use for women at high HIV risk Based on latest scientific evidence, the World Health Organization has updated the recommendations on contraceptive methods in women at high HIV risk: any form of reversible contraception is allowed without increasing their risk of sexually transmitted infections
HIV
Fully funded by 
Content independently selected
Latest Updates